Recombinant adenovirus high expression vector for promoting effective presentation of hantavirus fusion protein G1S0.7
A technology of recombinant adenovirus and fusion protein, which is used in the fields of recombinant adenovirus high expression vector, immunology and immune applications, and molecular biology, and can solve the problems of unsatisfactory immune level and low protein expression.
Patent Information
- Authority / Receiving Office
- CN · China
- Current Assignee / Owner
- Publication Date
- 2012-09-19
- Estimated Expiration
- Not applicable · inactive patent
Smart Images
Figure 1 Figure 2 Figure 3
Abstract
Description
technical field
[0001] The invention belongs to the field of biotechnology, and relates to related fields such as molecular biology, immunology and immune application. The invention relates to the reconstruction of an adenovirus recombinant transfer vector and a recombinant adenovirus high-expression vector for promoting the effective presentation of hantavirus fusion protein G1S0.7 to the pathogen of hemorrhagic fever with renal syndrome (HFRS). Background technique
[0002] Research status of hemorrhagic fever with renal syndrome and its genetic engineering vaccine:
[0003] Hemorrhagic fever with renal syndrome (HFRS) is caused by Hantavirus (HV) and is an acute viral infectious disease transmitted by rodents. Clinically, it is characterized by fever, bleeding and acute renal failure. Damage is the main feature. China is the country with the most severe HFRS epidemic in the world. It has the characteristics of a wide range of epidemics, a large number of patients, and a...
Examples
Embodiment Construction
[0025] The adenovirus expression system used in the present invention was purchased from Adeno-X of CLONTECH company TM system (Product No. K1650-1), the transfer vector is pShuttle.
[0026] The recombinant adenovirus transfer vector G1S0.7-pCAG used in the present invention was previously constructed by the applicant. (see patent application number 200910254561.3)
[0027] The recombinant adenovirus rAd-G1S0.7-pCAG and rAd-G1S0.7 used in the present invention were packaged and purified by the applicant in the early stage.
[0028] The bivalent HFRS inactivated vaccine used in the present invention was purchased from Zhejiang Tianyuan Company.
[0029] The Ub gene sequence inserted in the present invention is Ub up primer, Ub down primer upstream and downstream primers, pCMV-F3Ub as template, and 55°C as annealing temperature for PCR amplification, as shown in the attached figure 1 shown. The PCR product was ligated with the T-easy carrier overnight at 14°C, and the ligat...